Novartis AG
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof

Abstract:

The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.